This SuperSeries is composed of the SubSeries listed below.
Tissue-specific NETs alter genome organization and regulation even in a heterologous system.
Cell line, Treatment
View SamplesThe nuclear transmembrane proteins (NETs) NET29/TMEM120A, NET39/PPAPDC3 and NET47/TM7SF2 are able to reposition chromosomes towards/away from the nuclear envelope when overexpressed or knocked down in HT1080 cells. In this study we wanted to investigate the transcriptome changes after transfection of the full length NETs or a nucleoplasmic soluble fragment that does not localise to the nuclear envelope.
Tissue-specific NETs alter genome organization and regulation even in a heterologous system.
Cell line, Treatment
View SamplesThis SuperSeries is composed of the SubSeries listed below.
Constrained release of lamina-associated enhancers and genes from the nuclear envelope during T-cell activation facilitates their association in chromosome compartments.
Specimen part, Time
View SamplesActivation of T-cells induces dramatic changes in genome organisation and gene transcription. Here we identify changes in transcriptional profiles at 8h, 24h and 48 post activation
Constrained release of lamina-associated enhancers and genes from the nuclear envelope during T-cell activation facilitates their association in chromosome compartments.
Specimen part, Time
View SamplesThis SuperSeries is composed of the SubSeries listed below.
Tissue-Specific Gene Repositioning by Muscle Nuclear Membrane Proteins Enhances Repression of Critical Developmental Genes during Myogenesis.
Treatment, Time
View SamplesThe nuclear envelope transmembrane proteins (NETs) NET39/PPAPDC3, TMEM38A, TMEM214 and WFS1 are expressed or localise preferentially to the nuclear envelope in muscle cells. We knocked these proteins down using specific shRNAs and studied their effect in the diffentiation of the mouse C2C12 myoblast cell line.
Tissue-Specific Gene Repositioning by Muscle Nuclear Membrane Proteins Enhances Repression of Critical Developmental Genes during Myogenesis.
Treatment, Time
View SamplesEven though small cell lung cancer (SCLC) has entered the age of broad genomic analysis, platinum-based chemotherapy remains the standard care for SCLC. Topotecan is the only approved agent for recurrent or progressive SCLC (1). In the absence of well-defined genomic biomarkers, clinical efficacy signals in genomically distinct subsets of SCLC could have been missed. Serine/Arginine Splicing Factor 1 (SRSF1) is a member of SR protein family. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation (2). Whole exome and transcriptome sequencing of primary tumor SCLC from 99 Chinese patients has identified SRSF1 DNA amplification and mRNA over-expression which predicts poor survival in Chinese SCLC patients. In vitro and in vivo studies have demonstrated that SRSF1 is essential for tumorigenecity of SCLC and plays a key role in DNA repair and chemo-sensitivity. Overall design: We did RNAseq on 79 small cell lung cancer patients'' tumor sample and 7 normal lung tissue. We normalized the RNAseq data and did differential expression analysis. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation.
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.
No sample metadata fields
View SamplesWe used parkin –overexpressing MRC5 fibroblasts to investigate the role of mitochondria deficiency on senescence-associated gene expression. Overall design: RNA-seq analysis on proliferating and senescent Parkin-expressing MRC5 fibroblasts treated with CCCP (treated) or DMSO (Untreated).
Mitochondria are required for pro-ageing features of the senescent phenotype.
No sample metadata fields
View SamplesThis SuperSeries is composed of the SubSeries listed below.
c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.
Specimen part, Cell line
View SamplesAffymetrix exon arrays to identify genes that were differentially expressed after c-Jun inhibition in LPS cell line with and with no Jun amplification.
c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.
Specimen part, Cell line
View Samples